Pharmacyte Biotech Inc (OTCMKTS:PMCB) has confirmed the successful completion of its independent growth assessment of the cells; the Master Cell Bank (MCB). The clinical stage biotechnology company has indicated that its signature live-cell encapsulation technology, Cell-in-a-Box I ready for use. It will be utilized in an upcoming trial in patients with locally advanced non-metastatic and inoperable pancreatic cancer.
For a very long time, the company has been seeking for satisfactory production of the MCB. According to the Kenneth L. Waggoner, PharmaCyte’s Chief Executive Officer, this is a notable step towards the company’s efforts in its planned pancreatic cancer clinical trial. The CEO stated, “The availability of our preferred cell culture medium made a significant difference in our ability to achieve this milestone.”
The way is now open to populate the Master Cell Bank
The completion of the work was done by Eurofins Lancaster Laboratories in Lancaster, Pennsylvania. This is one of the largest commercial contract laboratories in the world and it is tasked with the provision of comprehensive laboratory services in the biopharmaceutical sectors. That said, Pharmacyte has authorized the production of the MCB by Eurofins, which will also advance the cells.
However, the completion of the MCB does not mean that all is done. The cells must undergo a variety of tests in order to fulfill regulatory requirements. Remember MCB contains far more vials of cells, which are expected to quicken PharmaCyte’s clinical development timeline. Satisfactory results from the vials of cells will then be shipped to Austrianova for further testing before PharmaCyte can apply for Investigational New Drug (IND) Application from the FDA.
PharmaCyte’s commitment to developing cellular therapies for cancer and diabetes
The biotech has been fighting too hard in safeguarding humanity from cancer and diabetes. Its aim is to have the “Cell-in-a-Box” technology used as a platform for developing therapies for several types of cancer and diabetes.
With the cancer therapy, genetically engineered human cells, which concert an inactive chemotherapy drug into its active or “cancer-killing” form are encapsulated together. The process is the same for Type 1 diabetes and insulin-dependent Type 2 diabetes and encapsulated human cells are genetically engineered to produce, supply and release insulin. All said and done, PharmaCyte says it is thrilled to be allied with Eurofins.